• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chairman and CEO Lemaitre George W sold $8,556,631 worth of shares (100,000 units at $85.57) and exercised 34,619 shares at a strike of $44.64, decreasing direct ownership by 3% to 1,827,003 units (SEC Form 4)

    5/20/25 7:11:24 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care
    Get the next $LMAT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    LeMaitre George W

    (Last) (First) (Middle)
    C/O LEMAITRE VASCULAR, INC.
    63 SECOND AVENUE

    (Street)
    BURLINGTON MA 01803

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    LEMAITRE VASCULAR INC [ LMAT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chairman and CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    05/16/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/16/2025 S 18,733 D $84.7661(1) 1,873,651 D
    Common Stock 05/19/2025 S 71,168 D $85.8557(2) 1,802,483 D
    Common Stock 05/19/2025 S 5,700 D $84.9395(3) 1,796,783 D
    Common Stock 05/20/2025 M 5,792(4) A $35.48 1,802,575 D
    Common Stock 05/20/2025 M 7,836(4) A $37.29 1,810,411 D
    Common Stock 05/20/2025 M 7,734(4) A $48.6 1,818,145 D
    Common Stock 05/20/2025 M 7,075(4) A $47.19 1,825,220 D
    Common Stock 05/20/2025 M 6,182(4) A $54.65 1,831,402 D
    Common Stock 05/20/2025 S 3,300 D $85.2416(5) 1,828,102 D
    Common Stock 05/20/2025 S 1,099 D $84.6926(6) 1,827,003 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $35.48 05/20/2025 M 5,792 12/20/2019(7) 12/20/2026 Common Stock 5,792 $0 0 D
    Stock Option (Right to Buy) $37.29 05/20/2025 M 7,836 12/02/2020(7) 12/02/2027 Common Stock 7,836 $0 7,836 D
    Stock Option (Right to Buy) $48.6 05/20/2025 M 7,734 12/11/2021(8) 12/11/2028 Common Stock 7,734 $0 7,733 D
    Stock Option (Right to Buy) $47.19 05/20/2025 M 7,075 12/12/2022(8) 12/12/2029 Common Stock 7,075 $0 16,269 D
    Stock Option (Right to Buy) $54.65 05/20/2025 M 6,182 12/08/2023(8) 12/08/2030 Common Stock 6,182 $0 20,373 D
    Explanation of Responses:
    1. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $84.40 to $85.01. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.
    2. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $85.32 to $86.25. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.
    3. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $84.60 to $85.23. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.
    4. Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II.
    5. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $85.00 to $85.91. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.
    6. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $84.23 to $84.88. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.
    7. This option is exercisable and vests over a five-year period at a rate of 20% on the first anniversary of the date listed in the table, with the balance vesting in equal annual installments over the remaining four years.
    8. This option is exercisable and vests over a four-year period at a rate of 25% on the first anniversary of the date listed in the table, with the balance vesting in equal annual installments over the remaining three years.
    /s/ Nathan Ulrich 05/20/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LMAT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LMAT

    DatePrice TargetRatingAnalyst
    2/28/2025Outperform → Perform
    Oppenheimer
    2/28/2025Outperform → Mkt Perform
    Barrington Research
    2/13/2025$95.00Equal Weight
    Wells Fargo
    10/15/2024$96.00Neutral
    Cantor Fitzgerald
    8/2/2024$85.00 → $105.00Buy
    Lake Street
    5/31/2024$100.00Buy
    ROTH MKM
    4/26/2024$59.00 → $75.00Hold → Buy
    Stifel
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $LMAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by LeMaitre Vascular Inc.

      SC 13G - LEMAITRE VASCULAR INC (0001158895) (Subject)

      10/22/24 3:49:21 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by LeMaitre Vascular Inc. (Amendment)

      SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)

      2/13/24 5:08:02 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by LeMaitre Vascular Inc. (Amendment)

      SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)

      2/12/24 3:02:21 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lemaitre Vascular downgraded by Oppenheimer

      Oppenheimer downgraded Lemaitre Vascular from Outperform to Perform

      2/28/25 8:28:09 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • Lemaitre Vascular downgraded by Barrington Research

      Barrington Research downgraded Lemaitre Vascular from Outperform to Mkt Perform

      2/28/25 7:39:54 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • Wells Fargo initiated coverage on Lemaitre Vascular with a new price target

      Wells Fargo initiated coverage of Lemaitre Vascular with a rating of Equal Weight and set a new price target of $95.00

      2/13/25 7:09:15 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $LMAT
    SEC Filings

    See more

    $LMAT
    Leadership Updates

    Live Leadership Updates

    See more

    $LMAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • LeMaitre to Present at the Bank of America Securities 2025 Healthcare Conference

      BURLINGTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that David Roberts, President, will present at the Bank of America Securities 2025 Healthcare Conference on Tuesday, May 13, 2024, at 5:00 PM PDT at the Encore at the Wynn Hotel in Las Vegas, NV. About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre

      5/5/25 4:39:09 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • LeMaitre Q1 2025 Financial Results

      BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q1 2025: Sales $59.9mm, +12% (+13% organic)Gross margin 69.2%, +60 bpsOp. income $12.6mm, +6%Op. margin 21%Earnings per diluted share $0.48, +10%Cash up $2.8mm sequentially to $302.5mm Grafts (+17%) and carotid shunts (+14%) drove sales growth. EMEA sales increased 18%, Americas 11%, and APAC 3%. Gross margin was 69.2% (vs. 68.6% in Q1 2024), due to higher average selling prices and manufacturing efficiencies. Operating income of $12.6mm wa

      5/1/25 4:05:32 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • LeMaitre Will Announce First Quarter 2025 Earnings Results May 1, 2025

      BURLINGTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its first quarter 2025 financial results on Thursday, May 1, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and ser

      4/7/25 3:56:16 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by LeMaitre Vascular Inc.

      10-Q - LEMAITRE VASCULAR INC (0001158895) (Filer)

      5/8/25 4:02:12 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • LeMaitre Vascular Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LEMAITRE VASCULAR INC (0001158895) (Filer)

      5/1/25 4:09:24 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by LeMaitre Vascular Inc.

      DEFA14A - LEMAITRE VASCULAR INC (0001158895) (Filer)

      4/17/25 10:12:37 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

      GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board. Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatm

      3/20/25 9:00:00 AM ET
      $LMAT
      $POCI
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Former Johnson & Johnson Executive Joins Advisory Board at Maitri Health Technologies

      Bridget Ross brings extensive experience in MedTech development and services;Joins advisory board of healthcare, logistics, capital markets and innovation leaders VANCOUVER, BC, March 23, 2021 /PRNewswire/ - Maitri Health Technologies Corp. ("Maitri") (CSE: MTEC) (FRA: D84), a global platform for healthcare supply security, today announced the appointment of Bridget Ross to its Advisory Board. Ms. Ross is currently CEO of ChroniSense Medical, Ltd., an Israel-based MedTech company and maker of wearable, medical-grade disease management devices. Ms. Ross serves as a Board Director for LeMaitre Vascular Inc. (NASDAQ: LMAT) and as a mentor for early stage MedTech companies through MassMEDIC and

      3/23/21 8:00:00 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • Chairman and CEO Lemaitre George W sold $8,556,631 worth of shares (100,000 units at $85.57) and exercised 34,619 shares at a strike of $44.64, decreasing direct ownership by 3% to 1,827,003 units (SEC Form 4)

      4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

      5/20/25 7:11:24 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • Director Ross Bridget A sold $312,000 worth of shares (3,750 units at $83.20) and exercised 3,750 shares at a strike of $30.00 (SEC Form 4)

      4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

      5/14/25 4:03:49 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Shadan Martha

      4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

      3/31/25 5:34:29 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    Financials

    Live finance-specific insights

    See more
    • LeMaitre Q1 2025 Financial Results

      BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q1 2025: Sales $59.9mm, +12% (+13% organic)Gross margin 69.2%, +60 bpsOp. income $12.6mm, +6%Op. margin 21%Earnings per diluted share $0.48, +10%Cash up $2.8mm sequentially to $302.5mm Grafts (+17%) and carotid shunts (+14%) drove sales growth. EMEA sales increased 18%, Americas 11%, and APAC 3%. Gross margin was 69.2% (vs. 68.6% in Q1 2024), due to higher average selling prices and manufacturing efficiencies. Operating income of $12.6mm wa

      5/1/25 4:05:32 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • LeMaitre Will Announce First Quarter 2025 Earnings Results May 1, 2025

      BURLINGTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its first quarter 2025 financial results on Thursday, May 1, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and ser

      4/7/25 3:56:16 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • LeMaitre Q4 2024 Financial Results

      BURLINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants, and services, reported Q4 2024 results, announced an increased quarterly dividend of $0.20/share (+25%), and provided guidance. Q4 2024 Financial Results Sales $55.7mm, +14% (+14% organic) vs. Q4 2023Gross margin 69.3%, +121 bpsOp. income $12.9mm, +26%Op. margin 23%Earnings per diluted share $0.49, +30%Cash up $175.8mm sequentially to $299.7mm Grafts (+23%), carotid shunts (+14%) and catheters (+12%) drove Q4 sales growth. APAC sales increased 21%, EMEA 18% and the Americas 12%. XenoSure patches received Chinese cardiac approval in December. The gross margin im

      2/27/25 4:05:29 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care